A single centre clinical trial of docetaxel and S-1 combination therapy as first line treatment in patients with advanced or recurrent gastric cancer

LI Qian,LIU Tian-shu,CUI Yue-hong,YU Yi-yi,FENG Yi,WANG Yan,GUO Xi,ZHUANG Rong-yuan,ZHOU Yu-hong,JIN Wen

DOI: https://doi.org/10.3969/j.issn.1007-3639.2012.08.007

2012-01-01

Abstract:Background and purpose:Advanced gastric cancer was incurable.S-1 and docetaxel were effective treatment for the advanced cancer.But toxicities of DCF regimen with standard dose were serious and poor tolerated.This clinical trial evaluated the toxicity and efficacy of first line chemotherapy regimen of low dose docetaxel and S-1 for advanced or recurrent gastric cancer.Methods:Forty eligible patients with advanced or recurrent adenocarcinoma of the stomach were enrolled and treated with intravenous docetaxel 40 mg/m2 on day 1 and oral S-1 80?mg/m2 per day on day 1 to 14 every 3 weeks.Treatment was continued until tumor progression or unacceptable toxicity.Tumor response was evaluated every 3 cycles or tumor progression suspected.Toxicity and clinical benefit response(CBR) of every cycle were recorded.Results:One remnant stomach recurrent cancer patient and 2 peritoneal metastasis patients withdraw in the first cycle because of hemorrhage in upper gastrointestinal and intestinal obstruction.Thirty-seven patients completed at least 1 cycle and received a total of 211 cycles of treatment(median 6,range 3-14).CBR was evaluated in 37 patients: 19(51.3%) effective,17(45.9%) stable and 1(2.7%) patients invalid.All 37 patients were evaluable for efficacy: 1(2.7%) complete response and 15(40.5%) partial responses,17(46.0%) stable disease,4(10.8%) progressive disease.The overall response rate was 43.2% and the tumor control rate was 89.2%.Median progression-free survival and median overall survival times were 6.0 and 11.5 months,respectively.The most common hematologic toxicities were leukopenia/neutropenia(50%),anemia(25%),thrombopenia(2.5%).The most common non-hematologic toxicities were anorexia(50%),appetite loss(47.5%),nausea(30%).Less common toxicities included neurotoxicity(15%),alopecia(12.5%),hand-foot syndrome(7.5%),diarrhea(7.5%),hemorrhage of upper gastrointestinal(5.0%),allergic reaction(2.5%),vomiting(2.5%),abnormal liver function(2.5%).Most toxicities were Ⅰ/Ⅱ grade while few patients had Ⅲ/Ⅳ grade toxicities: 7(17.5%) leukopenia/neutropenia,3(7.5%) appetite loss,4(10.0%)nausea,3(7.5%) anorexia,1(2.5%) thrombopenia,1(2.5%) hemorrhage.2 patients had S-1 20% extenuation due to grade Ⅲ toxicity.Conclusion:lower dose of docetaxel combination with S-1 as a first line treatment for advanced or recurrent gastric cancer is highly effective and well tolerated.